Launch of Oncology & OMNI Biomarker Groups

Following the initiation of PHC, the PD Biomarker and Molecular Diagnostic groups integrated and then separated along therapeutic lines creating standalone groups for Oncology (OBD) and non-oncology (OMNI-BD). These groups were then accountable for all biomarker and diagnostic development from IND until approval and beyond. There was also a group in research accountable for Biomarker Discovery (BD-OMNI).